Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 275 publications.

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.

Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C. Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther. 2015 Dec 9;32(12):1248-62. doi: 10.1007/s12325-015-0270-9

Khan S, Zimovetz E, Healey P, Copley-Merriman K. Biologics in ulcerative colitis (UC): treatment guidelines, health technology assessments (HTA). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A633.

Lebwohl M, Sherif B, Mollon P, Williams N, Fox T, Papavassilis C, Strober B, Gottlieb A. Secukinumab relieves pain and anxiety in psoriasis: results of two phase 3 trials. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Elewski B, Williams N, Mollon P, Sherif B, Fox T, Papavassilis C, Puig L. Psoriasis skin clearance is associated with patient-reported impact. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Strober B, Mordin M, Mollon, P, Williams N, Fox T, Papavassilis C, Lebwohl M. Secukinumab demonstrates greater impact on patient global impression of change than etanercept in moderate to severe psoriasis. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015 Aug 10;33(23):2516-22.

Stull DE, McBride D, Houghton K, Finlay AY, Balp MM. Correlation between UAS7 categorical health states and DLQI score bands to assess burden of disease and response to treatment in chronic idiopathic/spontaneous patients (CIU/CSU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Stull DE, McBride D, Houghton K, Balp MM. Are changes in chronic urticaria symptoms and sleep experience correlated?: a post-hoc analysis from phase II trials of omalizumab in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Chang J, Ngai C, Odom DM, Radder CN, Kappeler C, Xu R, Qin S, Kim T, Li J. Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at the 2015 ASCO Annual Meeting; May 29, 2015. Chicago, IL.

Chang J, Odom D, Radder C, Kappeler C, Xu R-h, Qin S, Kim TW, Li J. A post-hoc health-related quality of life analysis of patients with metastatic colorectal cancer in the phase III CONCUR trial. Poster presented at the ASCO Gastrointestinal Symposium 2015; May 2015. Chicago, IL. [abstract] J Clin Oncol. 2015 May; 33(Suppl 3):a667.

Benson C, Chirila C, Graham J, Radder C, Zheng Q, Muser E, Woodruff K. Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.

Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.

Collins A, Hawe E, Vickers A, Mallya UG, McBride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.

Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.

Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Correlations between changes in urticaria activity score, dermatologic-related quality of life, and urticaria-specific quality of life: results from the Ph III trials of omalizumab in CIU/CSU patients. Poster presented at the American Academy of Dermatology 72nd Annual Meeting; March 21, 2015. Denver, CO.

Stull DE, McBride D, Houghton K, Balp MM. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.

Chang J, Odom DM, Radder CN, Kappeler C, Xu R, Qin S, Kim T, Li J. A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at the 2015 Gastrointestinal Cancers Symposium; January 15, 2015. San Francisco, CA.

Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled, Phase III trials of omalizumab. Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the European Academy of Dermatology and Venereology; October 11, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.

McLeod LD, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.

Sherif BN, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomised, double-blind, placebo-controlled phase III trials of omalizumab. Poster presented at the European Academy of Dermatology and Venereology; October 8, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.

Lebwohl M, Mordin MM, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2, 2014. Amsterdam, The Netherlands.

Chirila C, Ziemiecki RM, Davenport EK, Kaschinski D, Pfarr E, Palencia R. Health-related quality-of-life analysis for patients with type 2 diabetes mellitus treated with empagliflozin. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Changes in urticaria symptoms, dermatologic-related quality of life, and urticaria-specific quality of life: are they telling us the same thing about response to treatment for chronic spontaneous/idiopathic urticaria (CSU/CIU)? Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 2014. Copenhagen, Denmark.

Nabhan C, Byrtek M, Dawson KL, Zhou X, Ziemiecki RM, Zelenetz AD, Friedberg JW, Cerhan JR, Flowers CR. Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): prospective evaluation of 2650 US patients (pts). Poster presented at the ASCO; May 2014.

Stull D, McBride D, Houghton K, Finlay A, Balp MM. Correlation between changes in weekly disease severity score and quality of life scores in chronic spontaneous/idiopathic urticaria (CSU/CIU): are they equally informative about the response to treatment? Poster presented at the AAAAI Annual Meeting; February 28, 2014. San Diego, CA.

Martin P, Byrtek M, Dawson K, Ziemiecki RM, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Cancer. 2013 Dec 1;119(23):4129-36. doi: 10.1002/cncr.28350

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Link BK. PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: report from the National LymphoCare Study. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):4245. doi: 10.1182/blood.V122.21.4245.4245

Stull DE, McBride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.

Raspa M, Bishop E, Candrilli S, Mitra D, Sacco P, Petrillo J, Bailey D. US caregiver burden in Fragile X syndrome as a function of a health-state utility index. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A625.

Messiah SE, Lopez-Mitnik G, Winegar D, Sherif BN, Arheart KL, Reichard KW, Michalsky MP, Lipshultz SE, Miller TL, Livingstone AS, de la Cruz-Muñoz N. Effect of ethnicity on weight loss among adolescents 1 year after bariatric surgery. World J Diabetes. 2013 Oct 15;4(5):202-9. doi: 10.4239/wjd.v4.i5.202

Yardley DA, Hortobagyi GN, Lebrun F, Beck JT, Neven P, Baselga J, Ziemiecki RM. Patient-reported physical, emotional, and social functioning in advanced breast cancer: insights from BOLERO-2. Poster presented at the Breast Cancer Symposium; September 7, 2013. San Francisco, United States. Previously presented at the American Society of Clinical Oncology.

Hahn KA, Wise LA, Riis AH, Mikkelsen EM, Rothman KJ, Banholzer K, Hatch EE. Correlates of menstrual cycle characteristics among nulliparous Danish women. Clin Epidemiol. 2013 Aug 19;5(1):311-9.

Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375

Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.

Davis KL, Meyers J, Zhao Z, McCollam P, Murakami M. High-risk vascular disease in Japan: evidence on incidence and prevalence, patient characteristics, and treatment rates from a large Japanese claims database. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 Apr; 16(3):A277.

Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013 Feb 1;24(2):441-8.

Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiol Drug Saf. 2013 Feb 1;22(2):111-21.

Macdonald TM, Mackenzie IS, Wei L, Hawkey CJ, Ford I, Perez-Gutthann S. Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the Standard care versus Celocoxib Outcome Trial (SCOT). BMJ Open. 2013 Jan 29;3(1):e002295. doi: 10.1136/bmjopen-2012-002295

Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.

Martin P, Link BK, Byrtek M, Dawson K, Ziemiecki RM, Friedberg J. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 8, 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):3702. doi: 10.1182/blood.V120.21.3702.3702

Davis KL, Mitra D, Yen L. Clinical characteristics, treatment patterns, and resource utilization in a real-world European population with diverticulitis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A535-6.

Publications

How Can We Help You?